Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European…
For LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination Treatment as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not…
Relationship gives Sun Pharma access to Greater China market for Tildrakizumab China to become a key market in future with…
Tokyo, May 16, 2019: Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its…
In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Tokyo, August 05,…
Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide. Delhi, March 12,…